PROM SSCOL: Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students

Sponsor
Centre Hospitalier Universitaire de la Réunion (Other)
Overall Status
Completed
CT.gov ID
NCT04459221
Collaborator
(none)
355
1
2
13.9
25.5

Study Details

Study Description

Brief Summary

Cervical cancer (CCU) is the fourth most common cancer in women worldwide. In Reunion island, CCU is the third leading cause of cancer in women (standardized incidence rate on the world population (TIS) in 2013 of 10.3 / 100,000) and is the eighth deadliest cancer with a rate standardized mortality of 4.8 / 100,000, almost three times higher than in mainland France where it was 1.7 / 100,000 in 2018.

CCU results from infection with the human papillomavirus (HPV), which is the most common sexually transmitted viral infection.

CCU prevention is mainly based on cervical smear screening and anti HPV vaccination (VHPV) which has demonstrated its effectiveness on the prevalence of HPV carriage, but also on incidence of condyloma or intermediate grade dysplasia. Since HPV is mainly transmitted sexually, it is important to vaccinate before the start of sex.

In Reunion island, the HPV vaccination coverage rate is the lowest in France, estimated by Public Health France at 8.1% among girls aged 16 years in 2018, while the already low national average was established 23.7%.

Thus, in view of the epidemiological situation in Reunion island (high incidence and mortality for the CCU, very low VHPV coverage rate), we thought it would be interesting to study the impact of a health promotion program sex and prevention of sexually transmitted infections (STIs) including papillomavirus-related pathologies, with a program to promote HPV vaccination among young students in middle school.

Condition or Disease Intervention/Treatment Phase
  • Drug: Gardasil 9, 9-Valent Intramuscular Suspension
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
355 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
Actual Study Start Date :
Nov 1, 2020
Actual Primary Completion Date :
Jun 25, 2021
Actual Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Facilitating access to HPV vaccination

Drug: Gardasil 9, 9-Valent Intramuscular Suspension
access to HPV vaccination near the college in a health bus

No Intervention: promotion of HPV vaccination

Outcome Measures

Primary Outcome Measures

  1. Change the vaccination rate in girls [9 month]

    Number of girls having completed a complete vaccination schedule. Hypothesis: the intervention under study should increase the rate of vaccinated

Secondary Outcome Measures

  1. increase the vaccination rate in all student [9 month]

    number of student having completed a complete vaccination schedule

  2. increase the vaccination rate in all student [9 month]

    number of student having completed a incomplete vaccination schedule

Eligibility Criteria

Criteria

Ages Eligible for Study:
9 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • schooled in one of the classes drawn at random in the 2 colleges selected for the study,

  • members or beneficiaries of a social security scheme,

  • having agreed to participate in the study and whose parents or holder (s) of parental authority have signed a free, informed and written consent.

Exclusion Criteria:
  • under the age of 9, or over the age of 17 at inclusion,

  • with hypersensitivity to the active substances or to any of the excipients of the vaccine (Gardasil 9®),

  • with a permanent contraindication to vaccination.

  • having already initiated the HPV vaccination (complete or incomplete scheme). Students with an incomplete vaccination schedule will be referred to their attending physician to complete the missing dose (s).

  • pregnancy or breastfeeding (based on the declaration)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de la Réunion Saint-Pierre France 97448

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de la Réunion

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de la Réunion
ClinicalTrials.gov Identifier:
NCT04459221
Other Study ID Numbers:
  • 2020/CHU/05
  • 2020-002332-73
First Posted:
Jul 7, 2020
Last Update Posted:
Mar 2, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022